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Aims: Optimal diabetes care requires clear understanding of the incidence of hypoglycaemia in
real-world clinical practice. Current data on hypoglycaemia are generally limited to those
reported from randomised controlled clinical trials. The Hypoglycaemia Assessment Tool (HAT)
study, a non-interventional real-world study of hypoglycaemia, assessed hypoglycaemia in
27 585 individuals across 24 countries. The present study compared the incidence of hypogly-
caemia from the HAT study with other similarly designed, large, real-world studies.
Materials and Methods: A literature search of PubMed (1995-2017) for population-based stud-
ies of insulin-treated patients with type 1 or type 2 diabetes (T1D, T2D), excluding clinical trials
and reviews, identified comparable population-based studies reporting the incidence of
hypoglycaemia.
Results: The 24 comparative studies, including more than 24 000 participants with T1D and
more than 160 000 participants with T2D, varied in design, size, inclusion criteria, definitions of
hypoglycaemia and method of recording hypoglycaemia. Reported rates (events per patient-year
[PPY]) of hypoglycaemia were higher in patients with T1D than in those with T2D (overall T1D,
21.8-73.3 and T2D, 1.3-37.7; mild/non-severe T1D, 29.0-126.7 and T2D, 1.3-41.5; severe T1D,
0.7-5.8 and T2D, 0.0-2.5; nocturnal T1D, 2.6-11.3 and T2D, 0.38-9.7) and were similar to the
ranges found in the HAT study.
Conclusions: The HAT data on hypoglycaemia incidence were comparable with those from
other real-world studies and indicate a high incidence of hypoglycaemia among insulin-treated
patients. Differences in rates among studies are mostly explained by differences in patient
populations and study methodology. The goal of reducing hypoglycaemia should be a target for
continued educational and evidence-based pharmacological interventions.
KEYWORDS
hypoglycaemia, insulin therapy, observational study, systematic review, type 1 diabetes, type
2 diabetes
1 | INTRODUCTION
The ultimate goal of glycaemic management in both type 1 (T1D) and
type 2 diabetes (T2D) is achievement of individualized glycaemic goals
without hypoglycaemia, which remains a common and acute compli-
cation with antidiabetic medications, particularly exogenous insulin
therapy. In T1D and T2D, hypoglycaemia can limit the glycaemic con-
trol that patients achieve and, therefore, undermine the goal of
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preventing long-term complications.1–5 Furthermore, hypoglycaemia
has a well-established significant negative impact on well-being, pro-
ductivity and quality of life (QOL).6 Recent studies have confirmed
that, in addition to decreased overall health-related QOL, hypoglycae-
mia can negatively impact physical and mental well-being, limit mobil-
ity, lead to anxiety and depression, interfere with social activities,
result in missed work (absenteeism), impair performance while at work
(presenteeism) and decrease overall work productivity.7–12 In addition
to an economic burden for patients, hypoglycaemia is associated with
increased healthcare resource utilization and health-economic
burden.7–9 Severe hypoglycaemia events frequently result in emer-
gency/ambulance calls and hospital treatment and, hence, incur sub-
stantial healthcare costs.11–13
It is important to have a clear understanding of the true incidence
of hypoglycaemia in order to individually tailor glycated haemoglobin
(HbA1c) targets, to provide optimal clinical care, to facilitate health-
care resource planning and to develop targeted hypoglycaemia pre-
vention strategies.14 The incidence of hypoglycaemia is generally
reported from randomized controlled trials, from which patients with
comorbidities or frequent severe hypoglycaemia are typically
excluded, and many of the studies have a treat-to-target design. Con-
sequently, the application of findings to real-world settings may be
limited, and the prevalence and incidence of hypoglycaemia in clinical
trials may not reflect those in real-world clinical practice.14
The Hypoglycaemia Assessment Tool (HAT) study is one of the
largest real-world global hypoglycaemia studies conducted to date.
HAT is a large, international (27 585 patients with T1D or T2D in
24 countries across Europe, Asia, North America and South America),
non-interventional, 6-month retrospective, 1-month prospective
study to determine the extent of hypoglycaemia in both T1D and T2D
in clinical practice.15 This literature review aimed to collate and evalu-
ate the incidences of hypoglycaemia reported in current literature
concerning real-world insulin-treated diabetes populations. Findings
from similarly designed large observational studies identified in a liter-
ature search were to be compared with those of the HAT study with a
view to explaining any observed differences.
2 | MATERIALS AND METHODS
2.1 | Search strategy
We conducted an electronic literature search of the PubMed database
from January 1995 to December 2017 to identify population-based
studies, excluding clinical trials and reviews, of individuals treated with
insulin, with a design similar to that of the HAT study (clinicaltrials.gov
NCT02240355), in which the proportion of individuals experiencing
hypoglycaemia, or the rates of hypoglycaemic events, were reported
by patient questionnaires, diaries or patient records.
The search terms used were “diabetes OR diabetic, AND hypogly-
cemia OR hypoglycaemia OR hypoglycemic OR hypoglycaemic, AND
survey OR report OR questionnaire, AND rate OR incidence OR fre-
quency OR risk.” We included observational studies in which the
study population was a defined general population with T1D and/or
T2D. We did not apply any restrictions relating to language or classifi-
cation, definition or measurement of hypoglycaemia.
Following removal of duplicate publications, titles and abstracts
were reviewed to identify studies that met the inclusion criteria.
Where it was unclear from the abstract whether the inclusion criteria
were met, the full article was retrieved and reviewed. The reporting of
data regarding the following criteria was used to determine study rele-
vance: patient self-reported hypoglycaemia; incidence rates; observa-
tional studies and surveys; patient awareness of hypoglycaemia; fear
of hypoglycaemia; experience of hypoglycaemia and its impact on
QOL, productivity and healthcare utilization.
2.2 | Data extraction
Where data were available, we extracted the following for each study:
country, number of participants (T1D and T2D), type of insulin ther-
apy and duration of use, disease duration, HbA1c levels (% and mmol/
mol), patient inclusion criteria, definitions of hypoglycaemia if avail-
able/documented and incidence of hypoglycaemia (overall, mild/non-
severe, severe and nocturnal). Where data were not reported, no
attempt was made to contact the authors of the individual publica-
tions to retrieve additional data.
2.3 | Data analysis
Relevant data were summarized and descriptive comparisons were
made among studies, including the HAT study. The co-primary objec-
tives of this literature review were to explore rates of hypoglycaemia
(overall, severe and nocturnal) in individuals with T1D and/or T2D
within population-based studies and compare the results with hypo-
glycaemia data from the prospective HAT study, both global and
regional analyses.
3 | RESULTS
3.1 | Identification of studies
Results relating to the identification process for eligible studies are
summarized in Figure 1. In summary, the PubMed search yielded
721 citations. Following abstract analysis of potentially relevant stud-
ies, 653 studies were excluded. Following assessment of 65 full text
articles, 41 were excluded, leaving 24 studies, including HAT, that
were eligible for inclusion in the analyses. Ten studies, DIALOG,16
GAPP2 UK,17 GAPP2 Canada,5 COMPASS,18 DSP China,19
PANORAMA,20 JADE,21 survey of insulin adherence,22 the single cen-
tre study in India,23 and the ICU study24 primarily reported hypogly-
caemia prevalence in terms of the proportion of participants reporting
hypoglycaemia, rather than rates in events per patient-year (PPY);
thus, these studies are reported separately.
3.2 | Summary of studies included in the analysis
An overview of the studies identified is provided in Table S1. All
reported data are observational, with 13 studies being prospective,
nine being retrospective and two, including the HAT study, using a
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mixed methods, prospective/retrospective design. In total, the studies
included 24 468 participants with T1D and 160 046 participants with
T2D. Studies were published from 2007 to 2017 inclusively. The num-
ber of participants within each study ranged from 77 to 66 726.25,26
Studies were conducted globally (n = 4), in Europe (n = 12), North
America only (n = 1), South America (n = 1) and East/South East Asia
only (n = 6). Study length ranged from 1 week (self-reported non-
severe hypoglycaemic events in Europe3 and self-reported non-severe
hypoglycaemic events in Germany27) to 22 years (single centre survey
in Germany28). Studies variously reported rates of self-treated, overall,
mild/moderate, mild/non-severe and nocturnal, mild/non-severe and
severe, mild/non-severe and severe and nocturnal, overall and severe
and nocturnal, overall and mild/non-severe and severe and nocturnal
hypoglycaemia and severe hypoglycaemia. Definitions of hypoglycae-
mia varied among studies (Table S2).
3.3 | Evaluation of the HAT study and comparative
real-world clinical study designs
Table S1 highlights differences in study design, type of insulin therapy,
duration of prior insulin therapy, patient characteristics and inclusion
criteria, definition of hypoglycaemia and reporting/documentation
mechanism between the HAT study and real-world clinical studies
identified for comparison.
Half (12/24) of the studies included only patients with T2D; three
studies were specific to T1D only; and the remainder of the studies
included patients with T1D or T2D (n = 9). Although the HAT study is
one of the largest, real-world, global prospective hypoglycaemia stud-
ies with diaries conducted to date (n = 27 585), several other studies
involved large numbers of participants. The Predictable Results and
Experience in Diabetes through Intensification and Control to Target
[PREDICTIVE] study included 7420 patients with T1D and 12 981
patients with T2D;26 the A1chieve study included 66 726 patients
with T2D;29 and the JADE study included 18 589 patients with
T2D.21
Patient selection and inclusion criteria for the HAT study were
generally aligned with those of the other studies, that is, adult patients
with T1D and/or T2D who were currently undergoing treatment with
insulin.15 However, selected studies included patients less than
18 years of age (self-reported non-severe hypoglycaemic events in
Europe,3 self-reported non-severe hypoglycaemic events in
Germany,27 the A1cheive study,29 the UK self-reporting study,30 and
self-reported insulin adherence in Brazil22) or they included only
patients who were at least 40 years of age (the GAPP26,16,31 and the
PANORAMA20 studies).
Similar to the HAT study, the duration of prior insulin therapies in
these studies was generally more than 1 year, although some studies,
such as SOLVE, examined patients for whom basal insulin was initi-
ated. Some studies included patients with substantially longer expo-
sure. For example, the GAPP2 study in the UK included patients with
up to 20 years of insulin use.16 With the exception of the UK Hypo-
glycaemia study, which included patients with T1D duration of up to
40 years,32 the mean duration of diabetes (T1D: range, 16.4-30 years;
T2D: range, 4.3-17.3 years) and baseline HbA1c levels (T1D: range,
60.5 mmol/mL to 83.3 mmol/mol; T2D: range, 52-80.3 mmol/mol)
were also generally comparable.
The definitions of hypoglycaemia varied widely among studies
(Table S2) and only the HAT,15 DIALOG16, survey of self-reported
insulin adherence22 and HypoAna33,34 studies defined hypoglycaemia
in accordance with ADA definitions.35 Documentation was based pri-
marily on symptoms, while a limited number of studies (a self-reported
non-severe hypoglycaemia study in Europe,3 a self-reported non-
severe hypoglycaemia study in Germany,27 a single-centre study in
Germany,25 a basal insulin dose-timing study,25 an ICU cohort
study,24 the PREDICTIVE26 and HypoAna33,34 studies) required docu-
mentation with glucose thresholds defined.
The mechanisms used to report/document hypoglycaemic events
also varied among studies and generally involved recall, making use of
questionnaires, or patient diaries (the PREDICTIVE and A1chieve
studies), with only one study (UK Hypoglycaemia study32) using con-
tinuous glucose monitoring.
Data from real-world studies of patients with T1D were available
for Europe (a self-reported non-severe hypoglycaemic events study in
Europe,3 a self-reported non-severe hypoglycaemic events study in
Germany,27 the PREDICTIVE,26 DIALOG16 and HypoAna studies,33,34
a study by Kristensen et al.,36 the ICU cohort study,24 the UK Hypo-
glycaemia study,32 and the UK self-reporting study30), Japan25 and
Brazil.22
Real-world studies of patients with T2D included global studies
(GAPP2,31 A1chieve29 and SOLVE37), European studies (GAPP2 UK,17
a self-reported non-severe hypoglycaemic events study in Europe,3 a
self-reported non-severe hypoglycaemic events study in Germany,27
the PREDICTIVE26 and DIALOG16 studies, the UK Hypoglycaemia
study,32 a single-centre survey in Germany,28 the UK self-reporting
study,30 the PANORAMA20 and ICU cohort studies24), Asian/South
East Asian studies (Physicians' Routine Evaluation of Safety and Effi-
cacy of NovoMix 30 Therapy [PRESENT],38 COMPASS,18 Diabetes
Records identified in
PubMed search 
n=4738
Articles screened on
basis of abstracts
n=718
Full text articles assessed
n=65
Studies meeting inclusion criteria 
and included in systematic review
n=24
Excluded based
on abstract
n=653
Excluded based
on full text
n=41
Excluded based
on title or
duplication
n=4020
FIGURE 1 Flow chart of selection of studies for inclusion
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Disease Specific Programme [DSP] China19, the JADE study21, a
single-centre study in India,23 a basal insulin dose-timing study in
Japan25) and one study from North America (GAPP2 Canada5).
Data on hypoglycaemia should be evaluated in the context of
HbA1c. In many studies this was not reported, but there was very lit-
tle variation across studies in the values that were reported (Table S1).
3.4 | Proportions and rates of hypoglycaemia in the
HAT study vs other real-world studies
Data for hypoglycaemia rates in T1D and T2D are given in Tables 1
and 2, respectively, with the studies reporting rates, expressed here as
events PPY, separated from those reporting only the proportion of
patients affected. Both parameters were used in the HAT study. As
expected, the rates of overall, mild/non-severe, severe and nocturnal
hypoglycaemia in patients with T1D were higher than those in
patients with T2D in all studies. Across studies, reported rates ranged
as follows: T1D overall, 21.8 to 73.3 events PPY; mild hypoglycaemia,
29.0 to 126.7 events per PPY; severe hypoglycaemia, 0.7 to 5.8
events PPY; nocturnal hypoglycaemia, 2.6 to 11.3 events PPY and
T2D overall, 1.3 to 37.7 events PPY; mild hypoglycaemia, 1.3 to 41.5
events per PPY; severe hypoglycaemia, 0.0 to 2.5 events PPY; noctur-
nal hypoglycaemia, 0.38 to 9.7 events PPY. In the dose-timing study
in Japan, the frequency of hypoglycaemia (events/month) was
7.7  9.9 in patients with T1D and 1.3  3.3 in patients with T2D.25
The data concerning proportions affected are potentially less informa-
tive, as these will be impacted by the time interval over which the
evaluation was made; however, the proportions in the HAT study,
given for the 4-week prospective interval, are broadly comparable to
other studies, with a higher percentage of patients with T1D (83.0%)
vs patients with T2D (46.5%) reporting hypoglycaemia. Proportions of
hypoglycaemia reported in the HAT study are in line with other stud-
ies that reported hypoglycaemia prospectively. In the DIALOG study,
85.3% and 43.6% of patients with T1D and T2D, respectively,
reported hypoglycaemia prospectively over 30 days.16 In the
HypoAna study over 2 years,33 92.1% of patients with T1D reported
hypoglycaemia. And in the DSP China study,19 33.3% of patients with
T1D reported hypoglycaemia over 1 year. Patients with T1D and T2D
in the PREDICTIVE26 study reported slightly lower proportions of
hypoglycaemia over 4 weeks (21.8% and 3.1%, respectively). Among
patients with T2D, 8.1% included in the JADE study over 10 years
reported mild hypoglycaemia21 while, in the single-centre study in
India, 95.9% of patients reported at least one symptom of
hypoglycaemia.23
3.4.1 | T1D: Overall and mild/non-severe hypoglycaemia
Rates of overall and mild/non-severe hypoglycaemia were comparable
between the HAT study (77.3 events PPY) and the European T1D
real-world studies (~20-125 events PPY) (Table 1). From European
data in the global HAT study, Eastern and North European rates of
non-severe hypoglycaemia were also within range at 66.9 PPY and
91.6 PPY, respectively. Overall rates in the PREDICTIVE trial were
lower; however, in that study, the blood glucose definition of hypogly-
caemia was less than 2.8 mmol/L (50 mg/dL), whereas, in the HAT
study, various definitions were used and in the GAPP2 study, it was
undefined, and in other studies, such as HypoAna, it was less than
3.9 mmol/L (≤70.2 mg/dL).
3.4.2 | T1D: Severe hypoglycaemia
The rate of severe hypoglycaemia in the global HAT dataset was 4.9
events PPY, which is within the range of the other European studies
(0.7-5.8 events PPY) (Table 1). According to global HAT data, patients
in Europe had high rates of severe hypoglycaemia (Northern Europe,
3.4 PPY; Eastern Europe, 4.5 PPY). Rates were low in the European
self-reported study (0.7 events PPY),3 which may be explained by
selection bias, as this study used a web-based survey that may have
precluded elderly and otherwise frail patients from participation. The
relatively high rates in the HAT and Dialog studies may be explained
by anonymous reporting, reducing bias, or by the fact that annual
rates were calculated from shorter observation periods of 4 weeks.
The PREDICTIVE study also reported lower rates than the HAT study,
but used a more stringent definition of severe hypoglycaemia. While
both the HAT and HypoAna studies defined severe hypoglycaemia as
events requiring third-party assistance to administer carbohydrate,
glucagon or other resuscitative action, the PREDICTIVE study
required third-party intervention along with a blood glucose reading
less than 2.8 mmol/L (50 mg/dL) or reversal of symptoms after food
intake, glucagon or intravenous glucose.
3.4.3 | T1D: Nocturnal hypoglycaemia
Only three studies reported nocturnal hypoglycaemia in T1D. The
rates in the HAT study (11.3 events PPY) were higher as compared
with the HypoAna study (8.5 non-severe, 2.6 symptomatic and 3.3
asymptomatic events PPY) and the PREDICTIVE study (3.6 events
PPY) (Table 1). According to the HAT study, nocturnal hypoglycaemia
rates in Northern Europe were higher than those reported globally, at
12.9 PPY, and in Eastern Europe rates were lower, at 9.8 PPY.
3.4.4 | T2D: Overall and mild/non-severe hypoglycaemia
Rates of overall and mild/non-severe hypoglycaemia were similar,
between 19 and 40 events PPY, in the HAT19 and GAPP221 studies
and in two European self-reported studies.4,29 According to the HAT
study, Northern and Eastern Europe rates of non-severe hypoglycae-
mia were 18.1 PPY and 23.7 PPY, respectively. Other studies, such as
PREDICTIVE27, A1chieve29 and SOLVE,37 reported lower rates of 1.3
to 3.1 events PPY. These lower rates may reflect the fact that, in the
A1chieve study, 67.2% of patients were insulin-naïve at baseline,
whereas 100% of participants in the SOLVE study were insulin naïve
at baseline. Hence, the lower rates of overall hypoglycaemia in those
studies vs the HAT and GAPP2 studies may reflect different partici-
pant populations. As for the PREDICTIVE trial, the comparatively
lower rates may reflect more stringent hypoglycaemia criteria as com-
pared to the HAT and GAPP2 studies.
3.4.5 | T2D: Severe hypoglycaemia
Rates of severe hypoglycaemia in T2D were uniformly low across
most studies, ranging from 0.0046 to 0.7 events PPY, and were high-
est in the HAT study, at 2.5 events PPY. In Europe, rates were high at
1.3 PPY (Northern Europe) and at 2.2 PPY (Eastern Europe). In the
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HAT study, only 0.237 events PPY required hospitalization. Differ-
ences among the rates of severe hypoglycaemia probably reflect the
differences among studies, in the study populations and in the defini-
tions of hypoglycaemia used, as discussed above.
3.4.6 | T2D: Nocturnal hypoglycaemia
Rates of nocturnal hypoglycaemia were higher in the HAT (3.7 events
PPY) and GAPP2 (9.7 events PPY) studies than in the other studies
that reported rates, including PREDICTIVE, A1chieve, PRESENT and
SOLVE (0.4-0.7 events PPY). Rates were also high in European data-
sets from the HAT study; in Northern Europe, rates were 3.7 PPY and
in Eastern Europe, rates were 4.0 PPY. This is perhaps not surprising,
given the different populations included in the various studies. For
example, the GAPP2 study,21 which had the highest rates of nocturnal
hypoglycaemia, included participants who had undergone more than
5 years of insulin therapy, whereas studies with the lower rates,
including the PRESENT and SOLVE studies, included insulin-naïve
participants.
4 | DISCUSSION
This review of 24 real-world studies highlights the fact that reported
rates of overall, mild/non-severe, severe and nocturnal hypoglycaemia
are variable; however, most of this variability appears to be explained
by the type of participants included and by differences among studies
in the definitions of hypoglycaemia. Different data collection methods
(questionnaires, diaries and patient records) also contribute to some
variation in the level of detail available and to the reported rates of
hypoglycaemia. Recently, attention has been focused on the different
definitions that confound the ability to compare and translate study
data. This has led to the release of a joint ADA/EASD statement from
the International Hypoglycaemia Study Group calling for uniform defi-
nitions to be used in clinical trials.39 Clearly, this approach would also
contribute to the ability to draw meaningful comparisons across data
from real-world and epidemiological studies. Another source of varia-
tion in reported rates may arise from differences between retrospec-
tive and prospective reporting, whereby retrospective reporting is
potentially less accurate as the result of memory bias and inconsis-
tency in methods of data collection. Global data, from studies such as
GAPP2 and HAT, provide initial indications that rates of hypoglycae-
mia in some regions of the world may be higher than previously sug-
gested, but further regional real-world studies are required to
confirm this.
4.1 | Relationship to other literature
Other than the individual studies identified in this analysis, there is a
paucity of literature focusing on hypoglycaemia rates among insulin-
treated patients in real-world settings. However, a recent systematic
review and meta-analysis of population-based studies involving
patients with T2D concluded that hypoglycaemia is highly prevalent
among insulin-treated patients with T2D. The meta-analysis described
a high degree of heterogeneity among studies, and estimated an inci-
dence of 23 events PPY for mild/moderate hypoglycaemia, and one
event PPY for severe hypoglycaemia. The rate for mild/moderate
hypoglycaemia was comparable to that reported in the HAT study
(19.3 overall events PPY) but the rate for severe hypoglycaemia was
lower than that reported in the HAT study (2.5 severe events PPY).14
While the HAT study included a truly global population, no previ-
ous hypoglycaemia incidence data were available for many partici-
pants. A further finding of the literature review was the limited global
reach of other real-world studies. Most studies, particularly in T1D,
were focussed on Europe and North America. The exceptions were
the GAPP2 (Global), A1chieve (Asia, North Africa, Middle East/Gulf,
Latin America and Russia) and PRESENT studies, a single-centre study
(India), the COMPASS and DSP China studies (China), the JADE study
(Hong Kong), a basal insulin dose-timing study in T2D (Japan) and a
self-reported insulin adherence study in T1D and T2D (Brazil). There-
fore, in order to identify regional differences in hypoglycaemia rates,
particularly in T1D, further real-world global studies are required to
identify the explanation for variations among regions, and interven-
tion studies are required to reduce the high rates of hypoglycaemia.
4.2 | Study limitations
Comparison of data from the component studies is not straightfor-
ward because of differences in inclusion criteria and definitions of
hypoglycaemia, as well as differences in reporting/documentation
mechanisms. There are multiple definitions of hypoglycaemia and con-
flicting data concerning the incidence of hypoglycaemia available in
the scientific literature.40 Combined with the fact that hypoglycaemic
events often go undetected, for a number of reasons, studies with
patient-reported data will unavoidably have variable outcomes if
hypoglycaemia events are not confirmed with blood glucose measure-
ments.40 Recall is an often-used but potentially inaccurate mechanism
to document hypoglycaemic events and a patient diary provides a
more realistic mechanism to record the incidence of hypoglycaemia. A
further confounding factor might be an unequal use of different insu-
lin regimens (eg, insulin analogues vs more traditional products) and
density of glucose measurement among studies. Limitations of the
methodology of this literature review are that it includes only publica-
tions that are listed in PubMed and the fact that results were
reviewed and included/excluded by multiple individuals.
4.3 | Implications of the study
The main clinical implication of this analysis is that hypoglycaemia is
more prevalent in real-world insulin-treated diabetes cohorts than is
indicated by data from randomized controlled trials. This is important
because hypoglycaemia has a significant impact on glycaemic control
and health-related QOL. Data from the HAT study broadly support
other studies in highlighting this issue. Concerning T1D, the HAT
study confirmed the seriousness of the hypoglycaemia challenge fac-
ing individuals, with overall rates of 73.3 events PPY, approximately
six events each month, five severe events PPY and 11 nocturnal
events PPY. Individuals with insulin-treated T2D will probably experi-
ence an average of 19 hypoglycaemic events overall annually, includ-
ing 2.5 severe and 3.7 nocturnal events according to data from the
HAT study.
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The current study highlights the need for uniform definitions
of hypoglycaemia, and for these uniform definitions to be used in
real-world studies, in order to draw accurate conclusions from the lit-
erature base. Standardization of hypoglycaemia definitions would be
particularly useful in making comparisons among regions, with a view
to informing the construction of regional guidelines. However, a fur-
ther implication of our literature review is that there is a need for
further study of hypoglycaemia rates in cohorts beyond Europe and
North America to support regional recommendations.
In conclusion, data from the HAT study contributes to the existing
literature by demonstrating that the global incidence of hypoglycae-
mia is high in all insulin-treated patient groups. There are inconsis-
tencies among studies in the rates reported, but these are explained
mostly by patient characteristics and by study methodology, leaving
an overall picture of a globally consistent clinical problem. We there-
fore suggest that the goal of reducing hypoglycaemia should be a tar-
get for continued educational and evidence-based pharmacological
interventions.
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